Product Compliance And Certification For Cosmetic Product In The Eu

Scope and evidence must be confirmed before any paid tests or filings.

The EU route for a cosmetic product begins with its intended use, composition and claims, not a certificate application. Regulation (EC) No 1223/2009 is the core law, but ingredient restrictions, borderline-product rules, chemicals restrictions and packaging obligations may change the launch decision. The map below is for a finished substance or mixture offered as a cosmetic in the EU; accessories sold with it require a separate classification check.

Short answer: an ordinary compliant cosmetic needs an EU-established responsible person, documented safety assessment and Product Information File (PIF), compliant manufacture and labelling, and CPNP notification before first placement on the EU market. CPNP is a notification, not product approval. Cosmetics as such do not receive CE marking or a mandatory EU product certificate. An ISO 22716 certificate may help demonstrate systems, but the legal requirement is good manufacturing practice (GMP), not the purchase of that certificate.

Importer/RP allocation: for cosmetics manufactured outside the EU, each EU importer is normally the responsible person for the product it places on the market; an importer may instead designate another EU-established person by a written mandate accepted in writing. For an EU-manufactured product, the EU-established manufacturer is normally responsible unless responsibility is validly delegated. Record the actual importer, mandate and label address rather than assuming a foreign supplier’s certificate establishes an EU responsible person.

1. Confirm the product is actually a cosmetic

Article 2(1)(a) covers a substance or mixture intended mainly to contact specified external body parts, teeth or oral mucosa to clean, perfume, change appearance, protect, maintain condition or correct body odours. Assess all marketing claims, instructions, mechanism of action, presentation and intended users before ordering a cosmetic safety report. An ingredient name or a supplier's foreign-market classification cannot decide the EU category.

Moisturising face cream or lip balm: ordinarily follows the cosmetics route where claims concern skin condition or appearance; a claim to treat eczema or disease demands a new medicinal-product borderline assessment.
Antibacterial hand gel: a “kills germs/disinfects” presentation raises a potential biocidal-product route, unlike a product sold primarily to clean or perfume hands. Classification is fact-specific.
Sunscreen: generally remains a cosmetic, but UV filters and claims require product-specific review; it is not automatically a medical device because UV protection is mentioned.
Cosmetic bundled with an LED/electrical tool: classify the cosmetic mixture and the device/accessory separately; other CE legislation may apply to the tool, never by default to the cream.

For borderline cases, preserve proposed claims and packaging and compare the Commission's non-binding borderline guidance; the competent authority's case-specific view, rather than marketing language alone, can be decisive.

2. EU cosmetic product: cross-regime decision matrix

Trigger in this product	Governing layer and decision	Evidence or action before launch
Cosmetic purpose and supply in EU	Regulation 1223/2009: identify EU responsible person under Article 4; safety, GMP, PIF, CPNP and label duties follow.	Product identity, supply-chain roles, signed responsible-person appointment where relevant.
Formula contains restricted substances, pigments, preservatives or UV filters	Check current Annexes II–VI, Article 15 CMR provisions and later amendments; an INCI entry in CosIng is not an authorisation.	Full quantitative formula, substance identifiers, use levels, impurities, restrictions for body site and product type.
Drug-like, therapeutic, disinfecting or device-like promise	Reopen classification under medicines, biocides or medical-device rules, as facts require; cosmetic notification cannot regularise a misclassified product.	Every claim, directions, packaging mock-up, intended action and supporting evidence.
Ingredient qualifies as a nanomaterial	Article 16 can require a separate six-month advance notification in addition to Article 13 CPNP; statutory exceptions apply, notably certain regulated colourants, preservatives and UV filters.	Particle characterization, nano status, Annex checks and Article 16 applicability decision.
Intentionally added synthetic polymer microparticles	Assess REACH Annex XVII restriction as amended by Regulation 2023/2055, including the use category, exemptions and phased dates; do not assume every polymer is banned.	Polymer and particle specifications, purpose, release pathway and relevant transition date.
Jar, tube, carton or e-commerce pack	Packaging and Packaging Waste Regulation (EU) 2025/40 applies generally from 12 August 2026, with requirements phased by article; packaging producer/EPR duties also need market-by-market checking.	Packaging composition, supplier declarations, business role and each destination country's producer-registration position.
Product sold with applicator, battery-powered item or other article	Separately screen the article against applicable product rules; only a CE-covered article should bear CE marking.	Bundle bill of materials, purpose and applicable legislation for each component.
PFHxA, its salts or related substances may occur in the formula or its raw materials	REACH Annex XVII PFHxA restriction under Regulation (EU) 2024/2462 applies to cosmetics from 10 October 2026 at the prescribed thresholds (25 ppb for PFHxA and its salts; 1,000 ppb for PFHxA-related substances). Check precise scope and grandfathering; this is not a ban on every PFAS.	Supplier declarations and, where risk warrants, analytical evidence for relevant materials; document the placement date and applicable exception.

2026 formulation and artwork watch: Commission Regulation (EU) 2023/1545 expands individual labelling of fragrance allergens. Products first placed on the EU market from 31 July 2026 must follow the new provisions; qualifying products placed earlier may continue to be made available until 31 July 2028 under the transitional conditions. Verify concentrations and whether the product is leave-on or rinse-off. Also recheck the Commission's current amendment list (including 2026/78 and 2026/909) instead of relying on an old supplier compliance letter.

Additional date-sensitive ingredient gates: Regulation (EU) 2026/78 applies from 1 May 2026. Regulation (EU) 2026/909 contains substance-specific transitions: for example, non-compliant cosmetics containing Triphenyl Phosphate or the UV filter DHHB may not first be placed on the market from 1 January 2027 and may not continue to be made available from 1 July 2028; dates for other entries can differ. For synthetic polymer microparticles, review both Regulation (EU) 2023/2055 and its 2026/1168 amendment; a revised solid-matrix exception applies from 22 June 2028. These provisions require a formula-by-formula review, not a single deadline for all cosmetics.

REACH microplastics date check: for covered intentionally added synthetic polymer microparticles, the restriction already applies to abrasive microbeads from 17 October 2023. Subject to the exact definitions and derogations, the principal cosmetic transition dates are 17 October 2027 for rinse-off products, 17 October 2029 for leave-on products and fragrance encapsulation, and 17 October 2035 for make-up, lip and nail products. A special consumer statement for affected make-up, lip and nail products applies from 17 October 2031. The amended solid-matrix derogation from 22 June 2028 is restricted to incorporation during an intended end use lasting at least one year. Do not apply a later cosmetic category date to abrasive microbeads or assume every polymer meets the legal microparticle definition.

3. Product-specific evidence pack: what the responsible person needs

A PIF is not merely a lab certificate. Under Articles 10–11 and Annex I, it contains the product description, Cosmetic Product Safety Report (CPSR), manufacturing method and GMP statement, evidence supporting claimed effects where justified by their nature, and animal-testing data required by Article 11. It must be readily accessible to competent authorities at the responsible person's label address and retained for 10 years after the last batch is placed on the market.

Input to obtain	Why it determines the route
Locked master formula with percentages, CAS/EC identifiers and each ingredient's function	Screens Annex restrictions, exposure and allergens; a marketing INCI list alone lacks concentrations.
Supplier specifications, impurities/trace data and fragrance-allergen breakdown	Enables toxicological review, Annex III labelling and contaminant assessment.
Intended body sites, target users, dosage, frequency and leave-on/rinse-off status	Sets foreseeable exposure, warnings and thresholds.
Stability, microbial quality and preservative-efficacy data where warranted; packaging compatibility	Supports actual product safety and shelf-life decisions; testing selection depends on the formula and risk.
Manufacturing method, batch traceability and GMP evidence	Demonstrates reproducible manufacture and the required GMP approach; EN ISO 22716 is a recognised route, not a compulsory certificate.
Exact artwork, web claims and substantiation studies	Aligns classification, mandatory particulars and Regulation (EU) 655/2013 claims criteria.
Responsible-person and import/distribution arrangements, market list	Fixes Article 4 roles, PIF access, languages, notifications and packaging responsibilities.

The CPSR's Part A holds safety information and Part B the qualified assessor's evaluation and conclusion. Article 10(2) specifies safety-assessor qualifications. The assessor determines which testing or data gaps must be closed: a universal “one test for every cosmetic” package is not a legal substitute for a product-specific assessment.

4. Label and launch dependency gates

The label generally needs the responsible person's name/address, nominal content (subject to exceptions), durability date or period-after-opening as applicable, precautions, batch identification, function unless clear, and an ingredient list in the required common names. Indicate country of origin for imported cosmetics. Check Article 19 details and applicable Member State language rules for each sales market. The ingredient list uses the current EU glossary (updated by Implementing Decision (EU) 2025/1175); it is not itself proof of ingredient legality. Nanomaterial ingredients require the prescribed “(nano)” indication.

Separate PPWR label clock: the harmonised packaging-material sorting label under Article 12(1) of Regulation 2025/40 becomes applicable from 12 August 2028 or 24 months after the relevant implementing acts take effect, whichever is later; this is not the same as cosmetic ingredient labelling, nor does it remove existing national packaging and EPR requirements.

Freeze the product and claims. Sign off classification for the exact formula, intended use, presentation and bundle. Do not use CPNP to bypass a biocide or medicine question.
Assign responsibility and close ingredient checks. Identify the Article 4 responsible person and check Annexes and horizontal restrictions at the intended launch date.
Complete safety and PIF. Have a qualified assessor sign the CPSR, assemble traceable safety/GMP/claims evidence and make the PIF accessible at the stated EU address.
Approve market-specific artwork and packaging. Verify language, allergens, warnings, importer origin, product-specific restrictions and applicable packaging/EPR obligations; later PPWR harmonised sorting-label dates are not an automatic August 2026 cosmetic-label deadline.
Notify, then place on market. Submit Article 13 details to the free CPNP before first placement; perform any separate applicable Article 16 nano pre-notification in time. Retain the notification confirmation. There is no additional general national cosmetic notification after CPNP, although other national obligations may exist.

5. Changes and post-launch triggers

A permitted launch is not permanent permission for every variant. A new fragrance supplier, higher preservative level, new target body area or therapeutic advertisement can affect Annex compliance, exposure, claims or even classification. Reassess safety, PIF, label and CPNP data before rolling out a material change. Under Articles 5 and 23, the responsible person must also cooperate on corrective measures and report serious undesirable effects to the competent authority of the Member State where they occurred. Distributors have separate Article 6 duties.

Practical stop/go rule: do not ship while the EU responsible person is unidentified, the full formula is unavailable, the CPSR/PIF is incomplete, a prohibited ingredient is suspected, a borderline claim is unresolved, or mandatory packaging/label requirements remain unchecked. A supplier's “EU certified” declaration alone closes none of these gates.

Questions specific to EU cosmetics

Is CPNP registration a licence or an EU cosmetic certificate?

No. CPNP is a free mandatory notification under Article 13, not a pre-market authorisation or certification decision. It does not replace the responsible person, safety assessment, PIF or compliant label.

Can I use one EU notification and the same artwork in all 27 Member States?

A CPNP notification avoids additional general national cosmetic notification, but Article 19 makes some label particulars subject to national language rules. Check each destination's language and packaging-producer duties; one untranslated label is not automatically sufficient. There is an important EU-level exception: where a distributor, on its own initiative, translates any label element to comply with the law of another Member State for a product already placed on the market in one Member State, Article 13(3) requires that distributor to submit specified information via CPNP. This is not an additional national cosmetic registration.

Does a US or Asian safety certificate replace the EU CPSR?

No. Foreign tests and supplier data may contribute evidence, but a qualified safety assessor must produce the Article 10/Annex I CPSR for the precise EU formula and intended use. Imported cosmetics still need an EU responsible person.

What changes for my perfumed lotion after 31 July 2026?

For newly placed products, review the expanded Annex III fragrance-allergen disclosures under Regulation 2023/1545, including concentration thresholds and leave-on classification. The until-31-July-2028 sell-through rule is conditional on earlier placement; it is not a blanket extension for new launches.

Does “nano” automatically mean a six-month wait, and does the cream need CE?

Neither conclusion is automatic. Article 16 has specific coverage and exceptions; review the nanomaterial and its function. An ordinary cosmetic has no CE route, while an electrical accessory sold with it may need its own CE assessment.